

PTO-1449 REPRODUCED

**INFORMATION DISCLOSURE CITATION
IN AN APPLICATION**

(Use several sheets if necessary)

 ATTORNEY DOCKET NO.
GG119.1US

 APPLICATION NO.
Unassigned

 APPLICANT
Carl Risinger et al.

 FILING DATE
August 29, 2001

 GROUP
Unassigned

 1c971 U.S. PTO
09/29/01

09/29/01

U.S. PATENT DOCUMENTS

EXAM- INER INI- TIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
DB	AA	6,045,996	04-Apr-2000	Cronin et al.	435	6	
DB	AB	5,648,482	15-Jul-1997	Meyer	536	24.33	
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						

FOREIGN PATENT DOCUMENTS

EXAM INER INI- TIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
DB	AI	EP 0 759 476 A1	02-May-1995	Kamataki	C12Q 1/68		
DB	AJ	WO 91/10745	17-Jan-1991	Wolf et al.	C12Q 1/68		
	AK						

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

DB	AL	"Elucidation of the genetic basis of the common 'intermediate metabolizer' phenotype for drug oxidation by CYP2D6" Sebastian Raimundo et al. <i>Pharmacogenetics</i> 2000 10:577-581					
DB	AM	"Genetic mechanisms for duplication and multiduplication of the human CYP2D6 gene and methods for detection of duplicated CYP2D6 genes" Eva Lundquist et al. <i>Gene</i> 226 (1999) 327-338					
DB	AN	Abstract "DETECTION OF NOVEL MUTATIONS IN THE 5'-FLANKING REGION OF CYP2D6." Sebastian Raimundo et al. <i>European Journal of Clinical Pharmacology</i> (1999) 55:AS					
	AO						
	AP						

EXPRESS MAILING NO. EK748827497US

EXAMINER

Diana P. [Signature]

DATE CONSIDERED

2/29/04

Form PTO-1449

Docket Number 532592001900

Application Number 09/942,310

**INFORMATION DISCLOSURE CITATION
IN AN APPLICATION**

MAY 06 2003

(Use several sheets if necessary)

Applicant

Carl RISINGER, et al

Filing Date August 29, 2001

Group Art Unit 1634

Mailing Date May 2, 2003

U.S. PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Filing Date If Appropriate

FOREIGN PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Country	Class	Subclass	Translation YES NO
DRS	1.	08/2001	WO 01/55432	WIPO			

OTHER DOCUMENTS

(including author, title, Date, Pertinent Pages, Etc.)

Examiner Initials	Ref. No.	Title
DRS	2.	CYP Allele Nomenclature Committee, "CYP2D6 Allele Nomenclature" Internet Article, 'Online! 13 January 2002 retrieved from <http://www.imm.ki.se/cypalleles/> on 01/13/2002
	3.	Daly, A. et al., "Nomenclature for Human CYP2D6 Alleles" Pharmacogenetics 6(3):193-201 (1996)
	4.	Database Genbank 'Online! Human CYP2D6 Gene, 22 November 1994 retrieved from www.ncbi.nlm.nih.gov Database Accession No. M33388 [Abstract]
	5.	Johansson, I. et al., "Genetic Analysis of the Chinese Cytochrome P4502D Locus: Characterization of Variant CYP2D6 Genes Present in Subjects with Diminished Capacity for Debrisoquine Hydroxylation" Molecular Pharmacology 46:452-459 (1994)
	6.	Kimura, S. et al., "The Human Debrisoquine 4-Hydroxylase (CYP2D) Locus: Sequence and Identification of the Polymorphic CYP2D6 Gene, a Related Gene, and a Pseudogene" American Journal of Human Genetics 45(6):889-904 (1989)
	7.	Lovlie, R. et al., "Polymorphisms in CYP2D6 Duplication-Negative Individuals with the Ultrarapid Metabolizer Phenotype: a Role for the CYP2D6*35 Allele in Ultrarapid Metabolism?" Pharmacogenetics 11(1):45-55 (2001)
DRS	8.	Zanger, U. et al., "Comprehensive Analysis of the Genetic Factors Determining Expression and Function of Hepatic CYP2D6" Pharmacogenetics 11(7):573-585 (2001)

EXAMINER:

Dana R. [Signature]

DATE CONSIDERED:

2/29/04

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.